These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 38111040)

  • 1. Non-coding RNA methylation modifications in hepatocellular carcinoma: interactions and potential implications.
    Shi Q; Chu Q; Zeng Y; Yuan X; Wang J; Zhang Y; Xue C; Li L
    Cell Commun Signal; 2023 Dec; 21(1):359. PubMed ID: 38111040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma.
    Li D; Li K; Zhang W; Yang KW; Mu DA; Jiang GJ; Shi RS; Ke D
    Front Immunol; 2022; 13():918140. PubMed ID: 35833147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosstalk between m6A modification and non-coding RNAs in HCC.
    Qiu Z; Yuan X; Wang X; Liu S
    Cell Signal; 2024 May; 117():111076. PubMed ID: 38309550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Mechanism Underlying the ncRNA Dysregulation Pattern in Hepatocellular Carcinoma and Its Tumor Microenvironment.
    Xue C; Gu X; Bao Z; Su Y; Lu J; Li L
    Front Immunol; 2022; 13():847728. PubMed ID: 35281015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma.
    Liu T; Sun L; Li ZZ; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
    BMC Gastroenterol; 2023 May; 23(1):147. PubMed ID: 37170222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
    Xiao Y; Li J; Wu J
    BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction between m6A modification and noncoding RNA in tumor microenvironment on cancer progression.
    Wei L; Liu S; Xie Z; Tang G; Lei X; Yang X
    Int Immunopharmacol; 2024 Oct; 140():112824. PubMed ID: 39116490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.
    Wong CM; Tsang FH; Ng IO
    Nat Rev Gastroenterol Hepatol; 2018 Mar; 15(3):137-151. PubMed ID: 29317776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the Divergent Gene Expression Landscapes of m6A/m5C/m1A Methylation Regulators in Hepatocellular Carcinoma Through Single-Cell and Bulk RNA Transcriptomic Analysis.
    Liu HT; Rau CS; Liu YW; Hsieh TM; Huang CY; Chien PC; Lin HP; Wu CJ; Chuang PC; Hsieh CH
    J Hepatocell Carcinoma; 2023; 10():2383-2395. PubMed ID: 38164510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma.
    Heo MJ; Yun J; Kim SG
    Arch Pharm Res; 2019 Jan; 42(1):48-62. PubMed ID: 30610616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.
    Ren M; Fan B; Cao G; Zong R; Feng L; Sun H
    BMC Genomics; 2023 Dec; 24(1):776. PubMed ID: 38097948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of m6A epigenetic modifications in tumor coding and non-coding RNA processing.
    Wen T; Li T; Xu Y; Zhang Y; Pan H; Wang Y
    Cell Commun Signal; 2023 Dec; 21(1):355. PubMed ID: 38102645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
    Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma.
    Zhang C; Dai D; Zhang W; Yang W; Guo Y; Wei Q
    J Gastroenterol Hepatol; 2022 Nov; 37(11):2039-2050. PubMed ID: 36066844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Huang X; Qiu Z; Li L; Chen B; Huang P
    Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ncRNA-mediated fatty acid metabolism reprogramming in HCC.
    Xu K; Xia P; Chen X; Ma W; Yuan Y
    Trends Endocrinol Metab; 2023 May; 34(5):278-291. PubMed ID: 36890041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting non-coding RNAs and N
    Wu L; Zhang Y; Ren J
    Biochem Pharmacol; 2024 May; 223():116153. PubMed ID: 38513741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of RNA methylation in hepatocellular carcinoma.
    Bao Q; Zeng Y; Lou Q; Feng X; Jiang S; Lu J; Ruan B
    Cell Commun Signal; 2024 Apr; 22(1):204. PubMed ID: 38566136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. m
    Zhou Y; Jian N; Jiang C; Wang J
    Biomed Pharmacother; 2024 Oct; 179():117331. PubMed ID: 39191030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA m
    Wang Z; Zhou J; Zhang H; Ge L; Li J; Wang H
    Mol Oncol; 2023 Feb; 17(2):195-229. PubMed ID: 36260366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.